Nutriband Raises $1.75M from Warrant Exercise to Advance Abuse-Deterrent Opioid Patch

  • Nutriband exercised 272,671 warrants at $6.43 per share, raising $1.75M in gross proceeds.
  • Proceeds will fund clinical development and FDA NDA submission for AVERSA Fentanyl, an abuse-deterrent opioid patch.
  • AVERSA Fentanyl could reach peak annual US sales of $80M–$200M if approved.
  • Nutriband has no remaining tradable warrants after this exercise.

Nutriband's warrant exercise provides critical funding for its abuse-deterrent opioid patch, a product positioned to address the growing demand for safer pain management solutions. The FDA's stance on abuse-deterrent technologies and the competitive landscape for transdermal opioids will shape Nutriband's long-term prospects.

Regulatory Timing
The pace at which Nutriband secures FDA approval for AVERSA Fentanyl will determine its commercialization timeline.
Market Potential
Whether AVERSA Fentanyl can capture significant market share in the $80M–$200M opioid patch segment.
Execution Risk
How effectively Nutriband allocates the $1.75M in proceeds to advance its clinical and regulatory goals.